At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, 2-Way Crossover Study of the Effect of a Single Dose of Glycopyrrolate Inhalation Solution (GIS) on Lung Hyperinflation in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
In Brief
A Phase 4 clinical trial evaluating Glyocopyrrolate Inhalation Solution administered by Magnair and Placebo administered by Magnair for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 44 participants across 1 site.
Detailed Summary
A clinical study to investigate if a single dose of an approved drug product (glycopyrrolate Inhalation Solution) reduces trapped air in the lungs of participants with chronic obstructive pulmonary disease. This study is accepting male and female participants over the age of 40. The study will be conducted at one site located in the United States.
Study Details
Timeline
Interventions
glycopyrrolate Inhalation Solution 25mcg, single dose
Placebo Inhalation Solution